AlphaQuest LLC Decreases Holdings in IQVIA Holdings Inc. $IQV

AlphaQuest LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 86.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 662 shares of the medical research company’s stock after selling 4,388 shares during the period. AlphaQuest LLC’s holdings in IQVIA were worth $126,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of IQV. Asset Dedication LLC boosted its position in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after purchasing an additional 168 shares during the last quarter. Rothschild Investment LLC increased its position in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 124 shares during the last quarter. Root Financial Partners LLC bought a new position in shares of IQVIA in the 3rd quarter worth approximately $43,000. NewSquare Capital LLC boosted its holdings in shares of IQVIA by 185.3% in the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock worth $46,000 after buying an additional 189 shares during the last quarter. Finally, AllSquare Wealth Management LLC grew its position in IQVIA by 68.6% during the second quarter. AllSquare Wealth Management LLC now owns 312 shares of the medical research company’s stock valued at $49,000 after buying an additional 127 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Evercore reiterated an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a research report on Thursday, February 5th. Mizuho set a $266.00 price objective on IQVIA in a research note on Friday, January 9th. Barclays lowered their target price on IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Friday, February 6th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, BMO Capital Markets set a $250.00 price objective on IQVIA in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $238.20.

IQVIA Price Performance

IQV stock opened at $168.78 on Friday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. The company’s fifty day moving average price is $224.30 and its 200-day moving average price is $209.18. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a market capitalization of $28.74 billion, a PE ratio of 21.47, a price-to-earnings-growth ratio of 1.71 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.